RnA ReSet Pro Revenue and Competitors

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • RnA ReSet Pro's estimated annual revenue is currently $3.1M per year.(i)
  • RnA ReSet Pro's estimated revenue per employee is $162,000

Employee Data

  • RnA ReSet Pro has 19 Employees.(i)
  • RnA ReSet Pro grew their employee count by 6% last year.

RnA ReSet Pro's People

NameTitleEmail/Phone
1
Director Marketing OperationsReveal Email/Phone
2
Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.1M10%N/AN/A
#2
$20.5M760%N/AN/A
#3
$7.6M356%N/AN/A
#4
$1.1M8-80%N/AN/A
#5
$5.5M290%N/AN/A
#6
$0.7M50%N/AN/A
#7
$21.3M797%N/AN/A
#8
$31.1M11553%N/AN/A
#9
$49.6M16710%N/AN/A
#10
$7.6M35-8%N/AN/A
Add Company

What Is RnA ReSet Pro?

Dr. Carolyn Dean is a medical doctor and naturopath. She’s the author of over 35 books including best seller The Magnesium Miracle along with IBS for Dummies, Hormone Balance, Death by Modern Medicine, and 110 Kindle books. In 2015, she launched RnAReSet and brought her 40 years of experience into her proprietary, unique formulations that give every individual at any stage of wellness or illness the necessary building blocks for sustained health, vitality and well-being.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$3.1M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RnA ReSet Pro News

2022-04-13 - Postpartum Depression Has Been Closely Linked With The Immune System, Study Finds

B-cells also send out both pro- and anti-inflammatory signals. ... to identify the B-cell variations, namely RNA sequencing, DNA genotyping,...

2022-04-13 - Study shows important change in B-cells in women with PPD

Researchers used RNA sequencing, DNA genotyping, and assessment of ... Activated B-cells then produce antibodies, and also secrete pro- and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M200%N/A
#2
N/A225%N/A
#3
$3.8M24-17%N/A
#4
$4.3M25-11%N/A
#5
$3.5M25-4%N/A